Evidence map›Paper›PMID 35382232›Full record

ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2022

Instrumental validation of free water, peak-width of skeletonized mean diffusivity, and white matter hyperintensities: MarkVCID neuroimaging kits.

Pauline Maillard, Hanzhang Lu, Konstantinos Arfanakis, Brian T Gold, Christopher E Bauer, Valentinos Zachariou, Lara Stables, Danny J J Wang, Kay Jann, Sudha Seshadri and 17 more

Abstract read
In one paragraph

Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Cognitive reserve against vascular contributions to cognitive impairment and dementia: A scoping review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  14. Article
  15. Elevated AD biomarkers do not explain cognitive performance in a community-recruited clinical trial cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Pauline MaillardDepartment of Neurology University of California, Davis Davis California USA.ORCID https://orcid.org/0000-0003-3516-6345
Hanzhang LuDepartment of Radiology Johns Hopkins University School of Medicine Baltimore Maryland USA.
Konstantinos ArfanakisDepartment of Biomedical Engineering Illinois Institute of Technology Chicago Illinois USA.
Brian T GoldDepartment of Neuroscience University of Kentucky Lexington Kentucky USA.
Christopher E BauerDepartment of Neuroscience University of Kentucky Lexington Kentucky USA.
Valentinos ZachariouDepartment of Neuroscience University of Kentucky Lexington Kentucky USA.
Lara StablesDepartment of Neurology University of California San Francisco San Francisco California USA.
Danny J J WangLaboratory of FMRI Technology (LOFT) Stevens Neuroimaging and Informatics Institute Keck School of Medicine University of Southern California Los Angeles California USA.
Kay JannLaboratory of FMRI Technology (LOFT) Stevens Neuroimaging and Informatics Institute Keck School of Medicine University of Southern California Los Angeles California USA.
Sudha SeshadriDepartment of Neurology Boston University School of Medicine Boston Massachusetts USA.
Marco DueringDepartment of Biomedical Engineering Medical Image Analysis Center (MIAC AG) University of Basel Basel Switzerland.
Laura J HillmerDepartment of Neurology University of New Mexico Albuquerque New Mexico USA.
Gary A RosenbergDepartment of Neurology University of New Mexico Albuquerque New Mexico USA.
Haykel SnoussiGlenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases University of Texas Health San Antonio San Antonio Texas USA.
Farshid SepehrbandLaboratory of FMRI Technology (LOFT) Stevens Neuroimaging and Informatics Institute Keck School of Medicine University of Southern California Los Angeles California USA.
Mohamad HabesGlenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases University of Texas Health San Antonio San Antonio Texas USA.
Baljeet SinghDepartment of Neurology University of California, Davis Davis California USA.
Joel H KramerDepartment of Neurology University of California San Francisco San Francisco California USA.
Roderick A CorriveauNational Institute of Neurological Disorders and Stroke Bethesda Maryland USA.
Herpreet SinghDepartment of Neurology Massachusetts General Hospital Boston Massachusetts USA.
Kristin SchwabDepartment of Neurology Massachusetts General Hospital Boston Massachusetts USA.
Karl G HelmerDepartment of Radiology Massachusetts General Hospital Boston Massachusetts USA.
Steven M GreenbergDepartment of Neurology Massachusetts General Hospital Boston Massachusetts USA.
Arvind CaprihanThe Mind Research Network Albuquerque New Mexico USA.
Charles DeCarliDepartment of Neurology University of California, Davis Davis California USA.
Claudia L SatizabalDepartment of Neurology Boston University School of Medicine Boston Massachusetts USA.
MarkVCID Consortium

Funding

UC Davis Alzheimer's Disease Core CenterP30AG010129 · NIA · UNIVERSITY OF CALIFORNIA DAVIS · PI DECARLI, CHARLES · 1991 to 2020
$28.3M
UC Davis Alzheimer's Disease Research CenterP30AG072972 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LEE-WAY JIN · 2021 to 2026
$25.2M
South Texas Alzheimer's Disease Research CenterP30AG066546 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Sudha Seshadri · 2021 to 2026
$24.0M
University of Kentucky Alzheimer's Disease Research CenterP30AG072946 · NIA · UNIVERSITY OF KENTUCKY · PI LINDA J VAN ELDIK · 2021 to 2026
$23.5M
PRECURSORS OF STROKE INCIDENCE AND PROGNOSISR01NS017950 · NINDS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Hugo Javier Aparicio, Jose Rafael Romero · 1985 to 2026
$22.9M
VCID Biomarkers Coordinating CenterU24NS100591 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI Steven M Greenberg · 2016 to 2026
$19.8M
Temporal Trends, Novel Imaging and Molecular Characterization of Preclinical and Clinical Alzheimer's Disease in the Framingham CohortsR01AG054076 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI DECARLI, CHARLES, SESHADRI, SUDHA · 2016 to 2020
$12.3M
THE UNIVERSITY OF TEXAS HOUSTON STROKE TRAINING PROGRAMT32NS007412 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI SAVITZ, SEAN I · 1998 to 2023
$4.6M
Imaging Cerebral and Retinal Microvasculature in Cerebral Small Vessel DiseaseUH3NS100614 · NINDS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KASHANI, AMIR H, RINGMAN, JOHN M · 2018 to 2020
$4.3M
Novel imaging and endothelial biomarkers of small vessel cerebrovascular diseaseUH3NS100608 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DECARLI, CHARLES, KRAMER, JOEL H · 2018 to 2020
$3.5M
Multimodal MRI biomarkers of small vessel disease for older persons with and without dementia.UH3NS100599 · NINDS · RUSH UNIVERSITY MEDICAL CENTER · PI ARFANAKIS, KONSTANTINOS, SCHNEIDER, JULIE A. · 2018 to 2020
$3.5M
Development of MRI microvascular biomarkers in cognitive impairment and dementiaUH3NS100588 · NINDS · JOHNS HOPKINS UNIVERSITY · PI ALBERT, MARILYN S., LU, HANZHANG · 2018 to 2020
$3.5M
NIA NIH HHS P30 AG010129NIA NIH HHS P30 AG066546NIA NIH HHS P30 AG072946NIA NIH HHS P30 AG072972NIA NIH HHS R01 AG054076NIA NIH HHS U01 AG052409NINDS NIH HHS R01 NS017950NINDS NIH HHS T32 NS007412NINDS NIH HHS U01 NS125513NINDS NIH HHS U24 NS100591NINDS NIH HHS UF1 NS100599NINDS NIH HHS UF1 NS125513NINDS NIH HHS UH2 NS100614NINDS NIH HHS UH3 NS100588NINDS NIH HHS UH3 NS100598NINDS NIH HHS UH3 NS100599NINDS NIH HHS UH3 NS100605NINDS NIH HHS UH3 NS100606NINDS NIH HHS UH3 NS100608NINDS NIH HHS UH3 NS100614
6 · The paper itself

Abstract

Introduction: To describe the protocol and findings of the instrumental validation of three imaging-based biomarker kits selected by the MarkVCID consortium: free water (FW) and peak width of skeletonized mean diffusivity (PSMD), both derived from diffusion tensor imaging (DTI), and white matter hyperintensity (WMH) volume derived from fluid attenuation inversion recovery and T1-weighted imaging. Methods: The instrumental validation of imaging-based biomarker kits included inter-rater reliability among participating sites, test-retest repeatability, and inter-scanner reproducibility across three types of magnetic resonance imaging (MRI) scanners using intra-class correlation coefficients (ICC). Results: The three biomarkers demonstrated excellent inter-rater reliability (ICC >0.94, Discussion: The three biomarker kits demonstrated very high inter-rater reliability, test-retest repeatability, and inter-scanner reproducibility, offering robust biomarkers suitable for future multi-site observational studies and clinical trials in the context of vascular cognitive impairment and dementia (VCID).

Indexed as

biomarkerdiffusion tensor imagingfree watermagnetic resonance imagingpeak‐width skeletonized mean diffusivitysmall vessel diseasevascular contributions to cognitive impairment and dementiaVCIDwhite matter hyperintensitywhite matter injury

Identifiers

PMID35382232
PMCPMC8959640

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.